Life in Suspension with Death: Biocultural Ontologies, Perceptual Cues, and Biomarkers for the Tibetan Tukdam Postmortem Meditative State.

This article presents two cases from a collaborative study among Tibetan monastic populations in India on the postdeath meditative state called tukdam (thugs dam). Entered by advanced Tibetan Buddhist practitioners through a variety of different practices, this state provides an ontological frame that is investigated by two distinct intellectual traditions-the Tibetan Buddhist and medical tradition on one hand and the Euroamerican biomedical and scientific tradition on the other-using their respective means of inquiry. Through the investigation, the traditions enact two paradigms of the body at the time of death alongside attendant conceptualizations of what constitutes life itself. This work examines when epistemologies of these two traditions might converge, under what ontological contexts, and through which correlated indicators of evidence. In doing so, this work explores how these two intellectual traditions might answer how the time course and characteristics of physiological changes during the postmortem period might exhibit variation across individuals. Centrally, this piece presents an epistemological inquiry delineating the types of valid evidence that constitute exceptional processes post-clinical death and their potential ontological implications.

Tibetan medicine Liuwei Muxiang pills (LWMX pills) effectively protects mice from chronic non-atrophic gastritis.

BACKGROUND: Chronic non-atrophic gastritis (CNG) is the most common type of chronic gastritis. If not actively treated, it may induce gastric cancer (GC). Western medicine is effective in CNG, but there are more adverse reactions after long-term medication, and it is easy to relapse after treatment, which affects patients' health and life. Tibetan medicine Liuwei Muxiang Pills (LWMX pills) is a traditional Tibetan medicine compound, which has a unique curative effect in the treatment of gastric inflammation, especially chronic non-atrophic gastritis. However, the mechanisms of LWMX pills for treatment CNG still remain poor known. PURPOSE: The aim of this study was to evaluate the therapeutic intervention potential of Tibetan medicine LWMX pills on CNG and explore its potential mechanisms in mice models. METHODS: The mice models was established to evaluate the therapeutic effect of LWMX pills on CNG. The main components of LWMX pills were analyzed by GC-MS. HE staining, immunohistochemistry, proteomics and Western Blot were used to analyze the potential mechanism of LWMX pills for CNG treatment. RESULTS: In the present study, LWMX pills containing costunolide, dehydrocostuslactone and antioxidants were found. IF results showed that the expression of ALDH1B1 in the control group was significantly lower than that in the model group in the gastric mucosa tissue, and the expression of ALDH1B1 was significantly lower in the 25 mg/ml LWMX Pills group (one month) and 25 mg/ml LWMX Pills group (two months) than in the model group. IHC revealed that model group samples expressed higher levels of Furin than 25 mg/ml LWMX Pills group samples, as evidenced by very strong staining of Furin in gastric mucosal cells. However, AMY2 staining in gastric mucosal cells did not differ significantly between the treated and control groups. the protein expression levels of these proteins were decreased in 25 mg/mL LWMX pills. Meanwhile, we found that the CAM1 protein expression in the in 25 mg/ml LWMX pills group (two mouths) was increased compared to the in 25 mg/ml LWMX pills group (one mouths).Western blotting showed that the protein expression levels of Furin, AMY2A, CPA3, ALDH1B1, Cam1, COXII, IL-6, IL-1ß were decreased in 25 mg/mL LWMX pills. Meanwhile, that the CAM1 protein expression in the in 25 mg/ml LWMX pills group (two mouths) was increased compared to the in 25 mg/ml LWMX pills group (one mouths). CONCLUSION: 25mg/ml LWMX pill treatment for one month had better therapeutic effect on mice CNG. Further proteomic results showed that LWMX pills maintain gastric function by inhibiting inflammation and oxidative stress, and we also found that LWMX pills regulate the expression of proteins associated with cancer development (Amy2, Furin).

Chasing dön spirits in Tibetan medical encounters: Transcultural affordances and embodied psychiatry in Amdo, Qinghai.

Although spirit possession is generally considered a psychiatric illness, the class of conditions designated as dön (Tib. gdon, "afflictive external influences," often glossed as "spirit affliction") in Tibetan medicine represents a distinctive paradigm for an etiology where physical and mental facets inhere in every illness. This study draws upon ethnographic fieldwork in eastern Tibet to examine two conditions that represent illness presentations at both ends of the dön spectrum: one that maps onto a biomedical etiology of stroke and another that presents in a way similar to schizophrenia. The case studies illuminate the forms of harmful external influences that (1) have physiological and psychological impacts that present as symptoms and (2) contribute to a pathogenesis common to both conditions. Our analysis considers the dual role of cultural affordances and bio-looping in the cultural presentation of the two conditions, as well as how the Tibetan medical tradition draws upon cultural, social, biological, and psychological determinants to understand this class of conditions. We also explore the implications the dön illness category has for biomedically oriented paradigms through the way in which it accounts for cultural models for both diagnosis and treatment of several chronic inflammatory conditions that have significant concomitant mental health presentations.

Dataset of materia medica in Sowa Rigpa: Tibetan medicine botanicals and Gawé Dorjé's classification system.

This article provides the most updated dataset of Latin botanical identifications for the materia medica in Tibetan medicine, known as Bö Luk Sowa Rigpa (Tib. Bod lugs gso ba rig pa), or the "Tibetan knowledge field of healing," often denoted in English simply as Sowa Rigpa. As one of the major scholarly Asian traditional medical systems, Sowa Rigpa is the principal health resource for populations across Tibetan regions of China, Mongolia, Bhutan, Nepal, India, and culturally-related areas of Russia. The geography represented by this medicinal plant dataset extends across the entire Tibetan plateau, its adjacent ranges, the wider transregional Himalayas, central Asia and much of the Indian subcontinent. Data collection drew from textual analysis of the seminal works of the Tibetan medical canon, including the Four Medical Treatises, Crystal Orb and Rosary among others; as well as the contemporary definitive work Stainless Crystal Mirror of Materia Medica by Gawé Dorjé. Study authors applied the same classification system as Gawé Dorjé, yet reanalyzed specimens according to a database cataloging research on regional herbarium botanical specimens, geographic distributions and regional plant chemistry studies, and confirming proper identification with the most current modern botanical taxonomies. Subsequently, almost 700 of the most commonly used materia medica were selected for compilation. Thus, this dataset represents updated botanical identifications and confirmations from both early and contemporary sources. Botanical specimen names were entered into spreadsheet format with Gawé Dorjé's categories listed alongside Deumar Tendzin Püntsok's early standard. Enclosed raw data are written in Unicode Tibetan font to retain fidelity to entries in the classical texts, with parallel columns in standard Wylie Tibetan transliteration and phonetic transcription. Latin botanical names are updated for each materia medica specimen using Kew's Medicinal Plant Names Services (Kew-MPNS) with missing entries supplied by World Flora Online (WFO) and Flora of China (FoC). This dataset is the first publicly available comprehensive ethnobotanical identification of Sowa Rigpa materia medica with Latin binomial nomenclature. This dataset was developed to inform botanical and pharmacological analysis of the Tibetan medical materia medica repertoire as well as make comparative analyses of related materia medica in other Asian medical systems.

Dataset of illness classifications in Sowa Rigpa: Compilations from the Oral Instructions Treatise of the Tibetan medical classic (Rgyud bzhi).

This article shares the comprehensive dataset and five visualized examples of disease categories in Tibetan medicine, or Sowa Rigpa (Tib. Gso ba rig pa), translated as the "knowledge field of healing." Sowa Rigpa is a scholarly Asian traditional medical system rigorously transmitted through canonical texts and oral teachings originating in Tibet with an extensive pharmacopeia, comprehensive treatment repertoire, and nuanced etiological explications of its nosology of diseases. This medical tradition is practiced across a broad region of Asia, particularly in Tibetan regions of China, Himalayan regions of India (Ladakh, Sikkim, Himachal Pradesh), Nepal, Bhutan, Mongolia, Russia, and recently in Europe and North America. The data herein depicts disease classifications listed in the encyclopedic compendium "Oral Instructions Treatise" (Man ngag rgyud) of the Tibetan medical classic, the Four Medical Treatises (Rgyud bzhi), compiled in written form during the twelfth century CE. Visualized examples depict etiological relations among diseases in five of the fifteen major categories of disease: rLung Illnesses, Béken Illneses, Pediatric Conditions, Eye Conditions and Tropical Infectious Diseases. Disease names were entered into spreadsheet format and categorized by etiological hierarchical structure. Data are written in Unicode Tibetan font to retain fidelity to entries in the classical text, with parallel columns in standard Wylie transliteration. Subsets of the data are visually depicted through a graphic platform called Interactive Tree of Life to demonstrate etiological associations. This dataset is the first publicly available enumeration of the specific diseases, classifications and etiological relationships from the Tibetan medical classic. The data are linked to the article entitled "Tibetan Medical Informatics: An Emerging Field in Sowa Rigpa Pharmacological & Clinical Research" (Dhondrup et al., 2020).

The transnational Sowa Rigpa industry in Asia: New perspectives on an emerging economy.

This article advances the hypothesis that "traditional" Asian pharmaceutical industries are rapidly growing in size and prominence in contemporary Asia, and identifies a lack of empirical data on the phenomenon. Addressing this gap, the article provides a quantitative outline and analysis of the Sowa Rigpa (Tibetan, Mongolian and Himalayan medicine) pharmaceutical industry in China, India, Mongolia and Bhutan. Using original data gathered through multi-sited ethnographic and textual research between 2014 and 2019, involving 232 industry representatives, policy makers, researchers, pharmacists and physicians, it assembles a bigger picture on this industry's structure, size and dynamics. Revealing a tenfold growth of the Sowa Rigpa pharmaceutical industry in Asia between 2000 and 2017, the study supports its initial hypothesis. In 2017, the industry had a total sales value of 677.5 million USD, and constituted an important economic and public health resource in Tibetan, Mongolian and Himalayan regions of Asia. China generates almost 98 percent of the total sales value, which is explained by significant state intervention on the one hand, and historical and sociocultural reasons on the other. India has the second largest Sowa Rigpa pharmaceutical industry with an annual sales value of about 11 million USD, while sales values in Mongolia and Bhutan are very low, despite Sowa Rigpa's domestic importance for the two nations. The article concludes with a number of broader observations emerging from the presented data, arguing that the Sowa Rigpa pharmaceutical industry has become big enough to exert complex transformative effects on Tibetan, Mongolian and Himalayan medicine more generally. The quantitative and qualitative data presented here provide crucial foundations for further scholarly, regulatory, and professional engagement with contemporary Sowa Rigpa.

Tibetan medicine for cancer: an overview and review of case studies.

INTRODUCTION: Tibetan medicine (TM) is a whole systems medical approach that has had growing interest in the West. However, minimal research, particularly with cancer, has been conducted. The purpose of this article is to provide an overview of TM and describe a clinical case review study to obtain preliminary evidence of TM's safety and effect on patients treated for cancer or hematologic disorders. METHODS: A retrospective case review was conducted in India and cases met the following inclusion criteria: (a) confirmed diagnosis of cancer or hematologic disorder by standard Western biomedical diagnostic tests, (b) either treated exclusively with TM or received insufficient Western treatment followed by TM and (c) were in remission or had stable disease at least 2 years after start of TM. RESULTS: Three cases were identified, 1 solid tumor and 2 hematologic diseases: Case 1--poorly to moderately differentiated adenocarcinoma of the stomach, positive lymph nodes and mucosal infiltration, with clear scans and excellent quality of life 29 months later ; Case 2--chronic myelogenous leukemia with normalization of hematologic labs within 3 months of starting TM and stable 4 years later; and Case 3--red cell aplasia improved significantly and reversed dependence on blood transfusions with TM. None of the cases experienced demonstrable adverse effects from TM. CONCLUSIONS: This limited case review found TM to be safe and have positive effects on quality of life and disease regression and remission in patients with cancer and blood disorders. Further exploration and investigation using rigorous methods is warranted.